FrancophonIA/ELRC3.0 huggingface dataset:
English: Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of NeuroBloc (see section 4.3).
Croatian: Bolesnici s neuromuskularnim poremećajima mogu biti pod povećanim rizikom od klinički značajnih učinaka, uključujući tešku disfagiju i kompromitirano disanje, pri uobičajenim dozama NeuroBloca (vidjeti dio 4.3).
English: Single dose pharmacology studies in cynomolgus monkeys have shown no effects other than the anticipated dose-dependent paralysis of injected muscles, together with some diffusion of toxin at high doses producing similar effects in neighbouring non-injected muscles.
Croatian: Farmakološka ispitivanja primjenom jedne doze u makaki majmuna nisu pokazala drugih učinaka osim očekivane paralize injektiranih mišića ovisno o dozi, zajedno s izvjesnom difuzijom toksina pri visokim dozama, što je slične učinke proizvelo i u susjednim mišićima koji nisu bili injicirani.
English: 0.5 ml, 1 ml or 2 ml solution in a 3.5 ml Type I glass vial, with siliconised butyl rubber stoppers oversealed by aluminium crimped caps.
Croatian: 0,5 ml, 1 ml ili 2 ml otopine u staklenoj bočici od 3,5 ml izrađenoj od stakla tipa I, sa silikoniziranim čepom od butilne gume zatvorenoj aluminijskom kapicom.
English: If you have further questions, please ask your doctor or pharmacist.
Croatian: Ako imate dodatnih pitanja, obratite se liječniku ili ljekarniku.
English: Mean at Week 4 P-Value*
Croatian: Srednja vrijednost u 4. tjednu 39,5 p-vrijednost*
English: if you are allergic to Botulinum Toxin Type B or any of the other ingredients of NeuroBloc (listed in section 6) if you have other problems with your nerves or muscles, such as amyotrophic lateral sclerosis (Lou Gehrig's disease), peripheral neuropathy, myasthenia gravis or Lambert-Eaton syndrome (muscle weakness or numbness or pain) if you have been experiencing shortness of breath or difficulty swallowing
Croatian: ako ste alergični na botulinski toksin tipa B ili neki drugi sastojak lijeka NeuroBloc (naveden u dijelu 6) ako imate drugih poteškoća sa živcima ili mišićima, kao što je primjerice amiotrofična lateralna skleroza (Lou Gehrigova bolest), periferna neuropatija, miastenija gravis ili Lambert-Eatonov sindrom (mišićna slabost ili obamrlost ili bol) ako ste osjetili nedostatak zraka ili otežano gutanje.
English: The most commonly reported adverse reactions associated with NeuroBloc treatment were dry mouth, dysphagia, dyspepsia, and injection site pain.
Croatian: Najčešće prijavljene nuspojave povezane s liječenjem NeuroBlocom bile su suha usta, disfagija, dispepsija i bol na mjestu primjene injekcije.
English: As with many biological/biotechnology proteins used as therapeutic agents, repeated administration of NeuroBloc may be associated with development of antibodies to Botulinum Toxin Type B in some patients.
Croatian: Kao kao i kod mnogih bioloških/biotehnoloških proteina koji se primjenjuju kao lijekovi, ponavljana primjena NeuroBloca može u nekih bolesnika biti povezana s razvojem protutijela na botulinski toksin tipa B.
English: What NeuroBloc is and what it is used for What you need to know before you use NeuroBloc How to use NeuroBloc
Croatian: Što je NeuroBloc i za što se koristi Što morate znati prije nego počnete primjenjivati NeuroBloc Kako primjenjivati NeuroBloc Moguće nuspojave
English: The solution is clear and colourless to pale yellow.
Croatian: Otopina je bistra i bezbojna do svijetlo žuta.
English: Do not use after the expiration date stamped on the vial.
Croatian: Nemojte upotrijebiti nakon isteka roka valjanosti navedenog na bočici.
English: Nervous system disorders dry mouth, headache torticollis (worsening from baseline), taste perversion
Croatian: Poremećaji živčanog sustava suha usta, glavobolja tortikolis (pogoršanje u odnosu na početno stanje), promijenjen osjet okusa
English: If the NeuroBloc solution is not clear and colourless/light yellow or if the vial appears damaged, the product should not be used, but discarded as Medical Biohazardous Waste in accordance with local requirements.
Croatian: Ako otopina NeuroBloca nije bistra i bezbojna/svijetložuta ili ako se čini da je bočica oštećena, lijek se ne smije upotrijebiti nego ga treba zbrinuti kao opasan medicinski otpad u skladu s lokalnim propisima.
English: P-Value* * Analysis of covariance, two-tailed tests, a = 0.05
Croatian: Srednja vrijednost u 4. tjednu 47,9 p-vrijednost* * Analiza kovarijance, dvostrani testovi, a = 0,05
English: From a microbiological point of view, unless the method of opening/dilution precludes the risk of microbial contamination the product should be used immediately.
Croatian: S mikrobiološkog stajališta, lijek treba upotrijebiti odmah osim kad metoda otvaranja/razrjeđivanja isključuje rizik mikrobiološke kontaminacije.
English: The following effects have also been reported during post marketing use: abnormal accommodation, ptosis, vomiting, constipation, flu-like symptoms, asthenia, angioedema, rash, urticaria and pruritus.
Croatian: Tijekom primjene nakon stavljanja lijeka u promet zabilježeni su također sljedeći učinci: abnormalna akomodacija, ptoza, povraćanje, konstipacija, simptomi nalik gripi, astenija, angioedem, osip, urtikarija i pruritus.
English: Neurobloc may impair the ability to drive or operate machinery in case of adverse reactions such as muscle weakness and eye disorders (blurred vision, eyelid ptosis).
Croatian: NeuroBloc može umanjiti sposobnost upravljanja vozilima i strojevima u slučaju nuspojava kao što su mišićna slabost i poremećaji oka (zamagljen vid, spuštena vjeđa).
English: A further randomised, multicentre, double-blind study was conducted to compare the efficacy of NeuroBloc (10,000 U) to Botulinum Toxin Type A (150 U) in patients with cervical dystonia who have never previously received a botulinum toxin product.
Croatian: Sljedeće randomizirano, multicentrično, dvostruko slijepo ispitivanje provedeno je kako bi se usporedila djelotvornost NeuroBloca (10 000 U) naspram botulinskog toksina tipa A (150 U) u bolesnika s cervikalnom distonijom koji nikada prije nisu primili pripravak botulinskog toksina.
English: The study met the pre-defined criteria for non-inferiority of NeuroBloc compared to Botulinum Toxin Type A, both in terms of mean TWSTRS total score at week 4 after first and second treatment sessions, and in terms of duration of effect.
Croatian: Ispitivanje je ispunilo prethodno definirane kriterije za neinferiornost NeuroBloca u usporedbi s botulinskim toksinom tipa A, i s obzirom na srednju vrijednost ukupnog rezultata na ljestvici TWSTRS za spazmodični tortikolis u 4. tjednu nakon prvog i drugog ciklusa liječenja, i s obzirom na trajanje učinka.
English: PHARMACOLOGICAL PROPERTIES 5.1 Pharmacodynamic properties
Croatian: FARMAKOLOŠKA SVOJSTVA 5.1 Farmakodinamička svojstva
English: Aspiration pneumonia caused by food particles or vomit entering into the lungs, and respiratory disease, have been reported after treatment with botulinum toxins (Type A and Type B).
Croatian: Aspiracijska upala pluća, prouzročena česticama hrane ili povraćanja koje uđu u pluća, i bolest dišnog sustava bile su zabilježene nakon liječenja botulinskim toksinima (tipa A i tipa B).
English: Co-administration of NeuroBloc and aminoglycosides or agents interfering with neuromuscular transmission (e.g. curare-like compounds) should be considered with caution.
Croatian: Istodobna primjena NeuroBloca i aminoglikozida ili lijekova koji ometaju neuromuskularni prijenos (npr. spojevi slični kurareu) mora se razmotriti s oprezom.
English: You may have muscle weakness or eye problems such as blurred vision or eyelid drooping after being given NeuroBloc.
Croatian: Možda ćete osjetiti slabost u mišićima ili teškoće s očima poput zamagljenog vida ili spuštene vjeđe nakon što primite NeuroBloc.
English: The non-inferiority of NeuroBloc compared to Botulinum Toxin Type A was further supported by a responder analysis where similar percentages of subjects showed improvement in the TWSTRS score at Week 4 of Session 1 (86% NeuroBloc and 85% Botox), and a similar proportion of subjects experienced at least a 20% decrease from baseline in the TWSTRS score at Week 4 of Session 1 (51% NeuroBloc, 47% Botox).
Croatian: A dodatno je poduprla analiza bolesnika s postignutim odgovorom, u kojoj je sličan postotak ispitanika pokazao poboljšanje rezultata na ljestvici TWSTRS u 4. tjednu 1. ciklusa liječenja (86% NeuroBloc i 85% Botox), a sličan udio ispitanika imao je najmanje 20%-tno smanjenje od početnih vrijednosti rezultata na ljestvici TWSTRS u 4. tjednu 1. ciklusa liječenja (51% NeuroBloc, 47% Botox).
English: In non clinical experiments, NeuroBloc solution has been diluted up to 6-fold without any resulting change in potency.
Croatian: U nekliničkim ispitivanjima otopina lijeka NeuroBloc razrijeđena je do 6 puta bez ikakve posljedične promjene u jačini.
English: NeuroBloc is indicated for the treatment of cervical dystonia (torticollis) in adults.
Croatian: NeuroBloc je indiciran za liječenje cervikalne distonije (tortikolisa) u odraslih.
English: If you are given more NeuroBloc than you should if you have been given more NeuroBloc than you need, some of your muscles that were not injected may feel weak or you may develop symptoms away from the injected muscles, like difficulty in swallowing or breathing.
Croatian: Ako ste primili više lijeka NeuroBloc nego što ste trebali, možete osjetiti slabost u nekim mišićima u koje niste primili injekciju ili su Vam se simptomi poput otežanog gutanja ili disanja pojavili dalje od mišića u koje ste primili injekciju.
English: Clear and colourless to light yellow solution.
Croatian: Bistra i bezbojna do svijetložuta otopina.
English: Skin allergies such as rash with or without paleness, redness, patches, severe itching; and skin eruptions such as welts or hives have also been reported after receiving NeuroBloc.
Croatian: Kožne alergije kao što su osip sa ili bez bljedila kože, crvenilo, ljuštenje, jaki svrbež i izbijanje promjena na koži kao što su uzdignuća ili koprivnjača također su prijavljene nakon primjene lijeka NeuroBloc.
English: Paediatric use (non approved): in children, clinically significant systemic toxicity has occurred at doses approved for the treatment of adult patients.
Croatian: Pedijatrijska primjena (neodobrena): primjenom doza odobrenih za liječenje odraslih bolesnika, u djece je nastupila klinički značajna sistemska toksičnost.
English: Immunogenicity data from three long term clinical studies indicate that approximately one third of patients develop antibodies, as determined by the mouse neutralisation/mouse protection assay dependent on duration of exposure (see section 5.1).
Croatian: Podaci o imunogenosti iz tri dugotrajna klinička ispitivanja pokazuju da približno jedna trećina bolesnika razvije protutijela, kako je ustanovljeno testom neutralizacije u miševa/zaštite miševa ovisno o trajanju izloženosti (vidjeti dio 5.1).
English: The secondary endpoints included Visual Analogue Scales (VAS) to quantify the Patient Global Assessment of change and the Physician Global Assessment of change, both from baseline to Week 4.
Croatian: Sekundarni ishodi uključili su vizualno analognu ljestvicu (Visual Analogue Scales, VAS) za kvantifikaciju bolesnikove opće procjene promjene i liječnikove opće procjene promjene, obje od početnih vrijednosti do 4. tjedna.
English: If you are not sure talk to your doctor or pharmacist.
Croatian: Ako niste sigurni, obratite se liječniku ili ljekarniku.
English: The initial dose of 10,000 U should be divided between the two to four most affected muscles.
Croatian: Početnu dozu od 10 000 U treba podijeliti između dva do četiri najzahvaćenija mišića.
English: The primary efficacy outcome variable for both studies was the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)-Total score (range of possible scores is 0-87) at Week 4.
Croatian: Primarna varijabla ishoda za djelotvornost u oba ispitivanja bio je ukupni rezultat (raspon mogućih bodova 0-87) na ljestvici za procjenu spazmodičnog tortikolisa (Toronto Western Spasmodic Torticollis Rating Scale, TWSTRS) u 4. tjednu.
English: Produced in Clostridium botulinum Serotype B (Bean Strain) cells.
Croatian: Proizveden u stanicama bakterije Clostridium botulinum serotip B (soj izoliran iz graha).
English: In the fertility studies the NOAEL was 300 U/kg/day for general toxicity in both males and females and 1000 U/kg/day for fertility and reproductive performance.
Croatian: U ispitivanjima plodnosti vrijednost NOAEL iznosila je 300 U/kg/dan za opću toksičnost i u mužjaka i u ženki, a 1000 U/kg/dan za plodnost i sposobnost reprodukcije.
English: United Kingdom
Croatian: Ujedinjeno Kraljevstvo i
English: Pack size of 1.
Croatian: Veličina pakiranja od 1 bočice.
English: NeuroBloc is used to treat an illness called cervical dystonia (torticollis).
Croatian: NeuroBloc služi za liječenje bolesti koja se naziva cervikalna distonija (tortikolis).
English: The initial dose is 10,000 U and should be divided between the two to four most affected muscles.
Croatian: Početna doza iznosi 10 000 U i treba je raspodijeliti na dva do četiri najzahvaćenija mišića.
English: SPECIAL WARNINGS THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN
Croatian: POSEBNO UPOZORENJE O ČUVANJU LIJEKA IZVAN POGLEDA
English: For instructions on dilution of the product before administration, see section 6.6.
Croatian: Za upute o razrjeđivanju lijeka prije primjene, vidjeti dio 6.6.
English: Read package leaflet for special precautions for handling, in-use storage and disposal.
Croatian: Pročitajte u Uputi o lijeku o posebnim mjerama opreza pri rukovanju, čuvanju u primjeni i zbrinjavanju.
English: Immunogenicity data from three long-term clinical studies indicate that approximately one third of patients develop antibodies, as determined by the mouse neutralisation/ mouse protection assay dependent on duration of exposure.
Croatian: Podaci o imunogenosti iz tri dugotrajna klinička ispitivanja pokazuju da približno jedna trećina bolesnika razvije protutijela, kako je ustanovljeno testom neutralizacije u miševa/zaštite miševa ovisno o trajanju izloženosti.
English: It is unknown whether Botulinum Toxin Type B is excreted in human breast milk.
Croatian: Nije poznato izlučuje li se botulinski toksin tip B u majčino mlijeko u ljudi.
English: Neuromuscular effects related to spread of toxin, distant from the site of administration have been reported (see section 4.8).
Croatian: Zabilježeni su neuromuskularni učinci povezani sa širenjem toksina dalje od mjesta primjene (vidjeti dio 4.8).
English: Within its shelf-life, the product may be removed from the refrigerator for one single period of up to 3 months at a temperature not above 25°C without being refrigerated again.
Croatian: Unutar roka valjanosti, lijek može biti izvan hladnjaka tijekom jednokratnog razdoblja do 3 mjeseca na temperaturi koja ne prelazi 25°C, bez ponovnog odlaganja u hladnjak.
English: The potency of this medicinal product is expressed in NeuroBloc 5000 U/ml.
Croatian: Jačina ovog lijeka izražena je u jedinici lijeka NeuroBloc 5000 po mililitru (U/ml).
English: In rabbits, the NOAEL was 0.1 U/kg/day for maternal effects and 0.3 U/kg/day for foetal effects.
Croatian: U kunića vrijednost NOAEL iznosila je 0,1 U/kg/dan za maternalne učinke i 0,3 U/kg/dan za fetalne učinke.
English: These studies have demonstrated the activity of NeuroBloc in both treatment-naïve patients, and patients who have previously received treatment with Botulinum Toxin Type A, including those that were considered clinically resistant to Botulinum Toxin Type A.
Croatian: Ta su ispitivanja dokazala djelovanje NeuroBloca i u bolesnika koji prethodno nisu bili liječeni i u onih koji su bili liječeni botulinskim toksinom tipa A, uključujući bolesnike za koje se smatralo da su klinički rezistentni na botulinski toksin tipa A.
English: The primary efficacy assessment was the TWSTRS Total score, and secondary efficacy assessments included VAS assessment of change evaluated by patient and investigator, conducted at 4, 8 and 12 weeks after treatment.
Croatian: Kao primarna procjena djelotvornosti služio je ukupni rezultat na ljestvici TWSTRS za procjenu spazmodičnog tortikolisa, a sekundarne procjene djelotvornosti uključivale su VAS procjene promjene koje su dali bolesnik i ispitivač, provedene u 4., 8. i 12. tjednu nakon liječenja.
English: NeuroBloc will be given to you by a doctor with specialist experience in the treatment of cervical dystonia and in the use of botulinum toxins.
Croatian: NeuroBloc će Vam dati liječnik specijalist s iskustvom u liječenju cervikalne distonije i primjeni botulinskih toksina.
English: In addition to improved function as demonstrated by a reduction in TWSTRS-total score, treatment with NeuroBloc was associated with a significant reduction in TWSTRS-Pain and pain VAS scores at each treatment session at weeks 4, 8 and 12 relative to baseline.
Croatian: Osim poboljšanja funkcije dokazanog smanjenjem ukupnog rezultata na ljestvici TWSTRS, liječenje NeuroBlocom bilo je povezano sa značajnim smanjenjem rezultata za bol na ljestvici TWSTRS i rezultata za bol na ljestvici VAS u svakom ciklusu liječenja u 4., 8. i 12. tjednu u odnosu na početne vrijednosti.
English: General disorders and administration site conditions injection site pain neck pain influenza like illness
Croatian: Opći poremećaji i reakcije na mjestu primjene bol na mjestu injiciranja bol u vratu bolest nalik gripi
English: For storage conditions after dilution of the medicinal product, see section 6.3.
Croatian: Uvjete čuvanja nakon razrjeđivanja lijeka vidjeti u dijelu 6.3.
English: Data from clinical studies suggest that efficacy is dose dependent, but these trials, because they were not powered for a comparison, do not show a significant difference between 5000 U and 10,000 U. Therefore an initial dose of 5000 U may also be considered, but a dose of 10,000 U may increase the likelihood of clinical benefit.
Croatian: Podaci iz kliničkih ispitivanja pokazuju da je djelotvornost ovisna o dozi, ali ta ispitivanja, budući da nisu uključivala usporedbu, ne pokazuju značajnu razliku između 5000 U i 10 000 U.
English: NeuroBloc is provided in vials for single use only.
Croatian: NeuroBloc je raspoloživ samo u bočicama za jednokratnu upotrebu.
English: Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Croatian: Lijek se izdaje na ograničeni recept (vidjeti Prilog I: Sažetak opisa svojstava lijeka, dio 4.2).
English: Solution for injection 1 vial
Croatian: Otopina za injekciju 1 bočica
English: The units expressed are Type B Units, which are not interchangeable with the units used to express the potency of other Botulinum toxin preparations.
Croatian: Te se jedinice odnose isključivo na tip B i ne smiju se zamijeniti za jedinice kojima se izražava jačina drugih pripravaka s botulinskim toksinom.
English: In the development studies, the No Observed Adverse Effect Dose Level (NOAEL) in rats was 1000 U/kg/day for maternal effects and 3000 U/kg/day for foetal effects.
Croatian: U razvojnim ispitivanjima doza bez opaženih štetnih učinaka (No Observed Adverse Effect Dose Level, NOAEL) iznosila je u štakora 1000 U/kg/dan za maternalne učinke i 3000 U/kg/dan za fetalne učinke.
English: Post marketing experience
Croatian: Iskustvo nakon stavljanja lijeka u promet
English: Co. Louth
Croatian: Louth
English: Decontaminate any spill with 10% caustic solution, or sodium hypochlorite (household chlorine bleach -2 ml (0.5%): 1 litre water) solution.
Croatian: U slučaju prolijevanja, dekontaminirajte površinu s 10% kaustične otopine ili otopinom natrijevog hipoklorita (klorno bjelilo za domaćinstvo - 2 ml (0,5%): 1 litra vode).
English: Two Phase III randomised, multicentre, double-blind, placebo-controlled studies were conducted in patients with cervical dystonia.
Croatian: U bolesnika s cervikalnom distonijom provedena su dva randomizirana, multicentrična, dvostruko slijepa, placebom kontrolirana ispitivanja faze III.
English: Single dose intramuscular toxicology studies have been performed in cynomolgus monkeys.
Croatian: Intramuskularna toksikološka ispitivanja jedne doze provedena su na makaki majmunima.
English: NeuroBloc is recommended for intramuscular administration only.
Croatian: NeuroBloc se preporučuje samo za intramuskularnu primjenu.
English: It contains the active ingredient ‘Botulinum Toxin Type B'.
Croatian: Lijek sadrži djelatni sastojak „botulinski toksin tipa B“.
English: The other ingredients are disodium succinate, sodium chloride, human serum albumin solution, hydrochloric acid (for pH adjustment) and water for injections.
Croatian: Drugi sastojci su dinatrijev sukcinat, natrijev klorid, otopina humanog serumskog albumina, kloridna kiselina (za podešavanje pH) i voda za injekcije.
English: Such dilutions with sodium chloride should be done in a syringe, pulling out the desired amount of NeuroBloc into the syringe first, and then adding sodium chloride to the syringe.
Croatian: Takva razrjeđenja s natrijevim kloridom treba provoditi u štrcaljki, i to tako da se najprije u štrcaljku izvuče željena količina NeuroBloca, a zatim se u štrcaljku doda natrijev klorid.
English: Place the absorbed toxin in an autoclave bag, seal it and process as Medical Biohazardous Waste in accordance with local requirements.
Croatian: Materijal s apsorbiranim toksinom stavite u vrećicu za autoklav, nepropusno je zatvorite i zbrinite kao opasni medicinski otpad u skladu s lokalnim propisima.
English: NeuroBloc must only be administered by intramuscular injection.
Croatian: NeuroBloc se smije primjenjivati samo kao intramuskularna injekcija.
English: The potency of Neurobloc is 5000 U/ml.
Croatian: Jačina NeuroBloca iznosi 5000 U/ml.
English: Disodium succinate, sodium chloride, human serum albumin solution, hydrochloric acid and water for injections.
Croatian: dinatrijev sukcinat, natrijev klorid, otopina humanog serumskog albumina, kloridna kiselina i voda za injekcije
English: Adverse reactions related to spread of toxin distant from the site of administration have been reported: exaggerated muscle weakness, dysphagia, dyspnoea, aspiration pneumonia with fatal outcome in some cases (see section 4.4).
Croatian: Nuspojave koje su prijavljene povezano sa širenjem toksina udaljeno od mjesta primjene bile su: pretjerana mišićna slabost, disfagija, dispneja, aspiracijska pneumonija sa smrtnim ishodima u nekim slučajevima (vidjeti dio 4.4).
English: Side effects related to spread of toxin distant from the site of administration have been reported (exaggerated muscle weakness, dysphagia, dyspnoea, aspiration pneumonia with fatal outcome in some cases) (see section 4.4).
Croatian: Prijavljene su nuspojave povezane sa širenjem toksina dalje od mjesta primjene (pretjerana mišićna slabost, disfagija, dispneja, aspiracijska pneumonija sa smrtnim ishodima u nekim slučajevima) (vidjeti dio 4.4).
English: NeuroBloc 5000 U/ml solution for injection.
Croatian: NeuroBloc 5000 U/ml otopina za injekciju.
English: And
Croatian: SAD
English: Eye disorders blurred vision
Croatian: Poremećaji oka zamagljen vid
English: Pregnancy, breast-feeding and fertility you will not normally be given NeuroBloc if you are pregnant or breast-feeding.
Croatian: U normalnim okolnostima nećete primiti NeuroBloc ako ste trudni ili dojite.
English: Read the package leaflet before use.
Croatian: Prije uporabe pročitajte Uputu o lijeku.
English: Studies have not been carried out in patients with hepatic or renal impairment.
Croatian: Nisu provedena ispitivanja u bolesnika s oštećenjem funkcije jetre ili bubrega.
English: Very Common
Croatian: Često
English: Individuals with known neuromuscular diseases (e.g. amyotrophic lateral sclerosis or peripheral neuropathy) or known neuromuscular junctional disorders (e.g. myasthenia gravis or Lambert-Eaton syndrome) must not be given NeuroBloc.
Croatian: NeuroBloc se ne smije davati osobama s ustanovljenom neuromuskularnom bolešću (npr. amiotrofičnom lateralnom sklerozom ili perifernom neuropatijom) ili s ustanovljenim poremećajima neuromuskularne sinapse (npr. miastenijom gravis ili Lambert-Eatonovim sindromom).